Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Low-Dose Naltrexone | Tesofensine | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | — | Research indicates 0.25-0.5 mg daily via oral administration. |
| Timing | — | Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia. |
| Cycle Duration | — | 12-24 week cycles. Monitor cardiovascular parameters throughout. |
| Evidence Level | Emerging | moderate_human |
Transient opioid receptor blockade that may increase endogenous endorphin signaling and modulate immune tone in off-label protocols.
Tesofensine (NS2330) is a triple monoamine reuptake inhibitor with affinity for dopamine (DAT), serotonin (SERT), and norepinephrine (NET) transporters. It suppresses appetite through indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways, reflecting additive effects of increased NE and DA activity. Tesofensine is a dual-action drug with both anorexigenic properties (appetite suppression) and metabolic properties (increased energy expenditure), silencing GABAergic hypothalamic neurons in the lateral hypothalamus.
Research indicates 0.25-0.5 mg daily via oral administration.
Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia.
12-24 week cycles. Monitor cardiovascular parameters throughout.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →